Indication intelligence, analysis and sector perception

Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT

November 7, 2018 6:52am

Athersys (ATHX) jumped +$0.01 before announcing a net loss of $9.7 M or $0.07 net loss per share, while ending the Q with cash position of $48 M. Until 12/6/18 Healios’ option is negotiation of the collaboration is completed, it’s still a question?

Audentes Therapeutics (BOLD) closed up +$0.43 before reporting a loss of $36.3 M or -$0.97 per share. The results did not meet “street” expectations for a loss of $0.88 per share.

Bellicum Pharmaceuticals (BLCM) closed down -$0.05 to $4.52 before reporting a net loss of $23.8 or -$0.55 per share. The expectation “beat” results were estimated to be -$0.57.

Global Blood Therapeutics (GBT) jumped +$1.12 before reporting a net loss of $43.1 M or -$0.83 per share compared with $28.6 M or -$0.66 per share for Q3/17. The results surpassed “street” expectations was for a loss of $0.84 per share.

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.